
Kezar Life Sciences
@KezarBio
Followers
475
Following
42
Media
310
Statuses
492
Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease.
South San Francisco, CA
Joined May 2019
Tomorrow, Kezar’s CEO, Chris Kirk, will participate in a fireside chat at the Jefferies Global Healthcare Conference! A webcast of the discussion will be available on our website's “Events & Presentations” section here: #JefferiesHealthcare
0
0
1
Today, we announced our participation in the Jefferies Global Healthcare Conference in #NewYorkCity next week. Learn more about our upcoming fireside chat in our latest press release here: #JefferiesHealthcare
0
0
0
Zetomipzomib is the only selective immunoproteasome inhibitor being evaluated in clinical trials for lupus nephritis. Learn more about the PALIZADE trial at #PALIZADEtrial #zetomipzomib #LupusNephritis
0
0
2
Tomorrow, Kezar’s CEO Chris Kirk will participate in a fireside chat at the Jefferies Global Healthcare Conference! A webcast of the discussion will be available on our website's “Events & Presentations” section here: #Jefferies #Healthcare #LN
1
1
2
Lupus nephritis is a frequent and moderate-to-severe complication of lupus affecting the kidneys. Learn about Kezar’s selective immunoproteasome inhibitor zetomipzomib being evaluated for those living with lupus nephritis: #LupusAwarenessMonth
0
0
2
Today, we announced our participation in the Jefferies Global Healthcare Conference in #NewYorkCity next week. Learn more about our upcoming fireside chat in our latest press release here: #Jefferies #Healthcare #Zetomipzomib
1
0
3
May is Lupus Awareness Month. Lupus is an autoimmune disease that causes chronic inflammation and organ damage. Lupus can affect anyone at any age and isn’t necessarily visible. Kezar invites you to promote lupus visibility by wearing purple this month!.#LAM #PutOnPurple
0
0
3
The PORTOLA Trial is evaluating zetomipzomib, a first-in-class agent for the treatment of autoimmune hepatitis. To learn more visit #PORTOLAtrial #zetomipzomib
0
0
3